Processa Pharmaceuticals (NASDAQ:PCSA) Upgraded by Zacks Investment Research to Hold

Processa Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Processa Pharmaceuticals Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of Processa Pharmaceuticals traded down -$0.04 on Wednesday, reaching $8.15. 0 shares of the stock traded hands, compared to its average volume of 75238. Shares of Processa Pharmaceuticals were trading at $8.15 on Wednesday. The firm’s 50 day moving average is $6.92 and its 200 day moving average is $7.92.Processa Pharmaceuticals has a 12 month low of $7.92 and a 12 month high of $14.24. While on yearly highs and lows, Processa Pharmaceuticals’s today has traded high as $8.24 and has touched $7.92 on the downward trend. See More Analyst Rating at: RATING

Processa Pharmaceuticals Earnings and What to expect: 

Processa Pharmaceuticals last announced its earnings data on August 12th, 2021. The reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.05. Processa Pharmaceuticals has generated ($1.38) earnings per share over the last year (($2.58) diluted earnings per share). Earnings for Processa Pharmaceuticals are expected to decrease in the coming year, from ($0.78) to ($0.97) per share. Processa Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

Earnings for Processa Pharmaceuticals are expected to decrease in the coming year, from ($0.78) to ($0.97) per share. The P/E ratio of Processa Pharmaceuticals is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Processa Pharmaceuticals is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Processa Pharmaceuticals has a P/B Ratio of 5.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Processa Pharmaceuticals (NASDAQ:PCSA) Moving Average Technical Analysis

5 day Moving Average is $7.96 And 5 day price change is $0.34 (4.35%)  with average volume for 5 day average is 87,780. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $7.93 and 20 day price change is $0.72 (9.69%) and average 20 day moving volume is 58,270. 50 day moving average is $6.92  and 50 day price change is $2.20 ( 36.97%)  and with average volume for 50 days is : 76,384. 200 day moving average is $7.92  and 200 day price change is $1.22 (0.176)  and with average volume for 200 days is : 75,188.

Other owners latest trading in Processa Pharmaceuticals :

  • On 8/17/2021 shares held by Millennium Management LLC were 54,154 which equates to market value of $0.44M and appx 0.00% owners of Processa Pharmaceuticals
  • On 8/17/2021 shares held by Citadel Advisors LLC were 10,106 which equates to market value of $83K and appx 0.00% owners of Processa Pharmaceuticals
  • On 8/16/2021 shares held by State Street Corp were 16,600 which equates to market value of $0.14M and appx 0.00% owners of Processa Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 8.78% for Processa Pharmaceuticals

See More Analyst Rating at: RATING